PharmiWeb Recruiter Blog

Castres, France and Cambridge UK, 25 September 2023 – Pierre Fabre Laboratories and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets.

Breakthrough Expands its International Footprint, Entering the Burgeoning Amsterdam Life Science Community in Partnership with the Amsterdam University Medical Center

Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change

Brand and visual identity demonstrate the best of Johnson & Johnson’s care and humanity, while capturing the Company’s passion and determination to improve the health of people worldwide

• Takeda’s Five New Partnerships Boost Total Global CSR Program Contributions to JPY 24.2 Billion (Approx. USD 167.5 million) Since Program Inception in 2016.

• More...

• UK site now set for clinical production of adeno-associated virus (AAV) vectors for gene therapy
• Highly experienced team ready to support ATMP innovators at all stages
• Offering comprehensive range of services from early process and analytical development through cGMP manufacturing for clinical trials

Stevenage, UK and Laupheim, Germany, September 13, 2023– Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that it has received the cGMP Manufacturing Compliance Certificate, following the successful inspection by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) at its UK site. The ATMP business was announced in early 2021 and the facility is located in the Cell and Gene Therapy Catapult’s Manufacturing Innovation Centre in Stevenage.

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules

WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the National Minority Quality Forum (NMQF), an independent not-for-profit research and education organization, today announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF’s Alliance for Representative Clinical Trials (ARC). The collaboration supports biopharmaceutical and biotech customers in meeting regulatory expectations to enroll and retain patients in clinical trials who more fully reflect real-world populations experiencing the disease or health condition being studied, including U.S. Food and Drug Administration requirements around diversity action plans.

The collaboration aims to identify disease-modifying interventions, with the goal of improving standards of care for people living with type 2 diabetes and cardiac fibrosis

• Bigfoot developed Bigfoot Unity, a smart insulin management system that features the first and only FDA-cleared connected insulin pen caps that turn data from a continuous glucose monitor (CGM) into clear and reliable insulin dosing recommendations displayed right on the insulin pen cap
• Acquisition will bring together two leaders in different aspects of diabetes care: CGM and insulin injection support
• Together, Abbott and Bigfoot will continue to advance technology-driven solutions for making diabetes management even more personal and precise

ABBOTT PARK, Ill. and MILPITAS, Calif., Sept. 5, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and Bigfoot Biomedical today announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes.